EFFICACY OF ACTH 4-9 ANALOG, METHYLPHENIDATE, AND PLACEBO ON ATTENTION DEFICIT DISORDER WITH HYPERKINESIS

HENDRIK J. BUTTER, 1,4 YVON LAPIERRE, 1,2,5, PHILIP FIRESTONE, 3 and ARTHUR BLANK, 3

Departments of 1 Psychiatry, 2 Pharmacology, and 3 Psychology, University of Ottawa, Ottawa, Ontario; 4 Centre hospitalier Pierre-Janet, Hull, Quebec; and 5 Royal Ottawa Hospital, Ottawa, Ontario, Canada.

(Final form, July 1984)

Abstract


1. The present study compared the efficacy of ACTH 4-9 analog, methylphenidate, and placebo on attention deficit disorder with hyperkinesia (HK) children with attention deficit disorder and psychometric measurements.

2. HK children were randomly placed into three groups, according to body weight, and treated with placebo, methylphenidate, and adrenocorticotropic hormone fractions (ACTH 4-9 analog).

3. The results revealed that HK children on methylphenidate manifested a significantly greater vasoM)tor reactivity, behavioral improvement, and learning receptivity than HK children taking ACTH 4-9 analog and/or placebo.

4. Future research implications with ACTH 4-9 and HK children are discussed.

Keywords: ACTH 4-9 analog, Methylphenidate, Attention Deficit Disorder

Abbreviations: Adrenocorticotropic hormone (ACTH); Hyperkinesis (HK); Conners's Short Form Rating Scale (CSS); Matching Familiar Figure Test (MFF); Memory for Design MFD.

Introduction

It is becoming increasingly apparent that short-chain polypeptides such as melanocyte stimulating hormone and analogues adrenocorticotropic hormone (ACTH) fractions (ACTH 4-9) influence both behavior and the electrophysiological activity of the brain.1 More precisely, ACTH 4-9 analog studies1-4 have reported enhancement of short-term visual memory, attention, self-rated competence, and observer-rated sociability. These behavioral and neurophysiological findings indicated that ACTH and its fractional analogues have direct, extra-adrenal effects on central nervous system functioning.

Attention deficit disorder with hyperkinesia (HK) is now quite well recognised as a clinical syndrome in children who manifest difficulties in attention, memory, and motivation, with or without hyperactivity.5

Studies6-8 investigating the management of the disorder have reported that methylphenidate reduces distractibility and impulsivity and improves selective attention in both home and school environments. Consequently, methylphenidate has become the usual chemotherapeutic strategy for children with this syndrome.
The objective of the present investigation was to compare ACTH 4-9 with placebo to determine whether or not the peptide improves measurements of attention and behavior in hyperkinesis children.

**Methods**

**Patient Population.** Thirty children were included in the study. They were all male, aged 6 to 12 years, and had a clinical diagnosis of attention deficit disorder with hyperkinesis (DSM III).

**Drug Administration.** This was a double-blind efficacy study comparing three groups of 10 boys, each group receiving a different drug over a 1-week period. Dosage was adjusted for body weight as illustrated in Table 1.

**Table 1**

<table>
<thead>
<tr>
<th>Parameter Taken to Study the Effects of ACTH 4-9 Analog, Methylphenidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight groups</td>
</tr>
<tr>
<td>Weight ranges (kg)</td>
</tr>
<tr>
<td>No. of subjects</td>
</tr>
<tr>
<td>Fixed doses of drug (mg)</td>
</tr>
<tr>
<td>Dose ranges (mg/kg)</td>
</tr>
</tbody>
</table>

**Experimental Procedure.** Seven-day drug-free period was followed by a week of placebo treatment. After the placebo washout, treatment was assigned in a double-blind and random manner to either ACTH 4-9, methylphenidate, or placebo.

**Assessment Instruments.** Clinical and laboratory instruments: Summary description of ACTH 4-9 dependent variables as illustrated in Table 2.

**Statistical Analysis.** Table 2 illustrates the type and procedure of quantification used for each index in the current study. In order to explore the pre-residual and post-residual drug change, the BMPD-P2V program was used.

**Results**

The results revealed that the three treatment groups on each of the dependent variables, only the digital blood flow measured at the end of the experimental session and the Conners' HK index were significantly different on the predrug and postdrug comparisons. HK children treated with methylphenidate had a significant lower digital blood flow and hyperactivity index after 1 week of drug administration than HK children on placebo and ACTH 4-9 analog.

Electroencephalogram, hematology, blood chemistry, and urinalysis were within normal limits prior to treatment and remained so after treatment for all three weight and drug groups.

**Discussion**

The primary purpose of the present investigation was to compare three groups of HK children on placebo, methylphenidate, and ACTH 4-9 in a randomized group design.

Despite the limitations of the sample size, short time exposure, and difficulties of available psychometric instruments, these results suggest that methylphenidate produces a significantly higher pulse rate and lower skin conductance in comparison to ACTH 4-9 and/or placebo. This is consistent with earlier reported findings on methylphenidate efficacy.
ACTH 4-9 and methylphenidate on attention deficit disorder

Table 2
List of ACTH 4-9 Dependent Variables

<table>
<thead>
<tr>
<th>System</th>
<th>Index</th>
<th>Quantification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychometric</td>
<td>Memory for design</td>
<td>msec</td>
</tr>
<tr>
<td></td>
<td>Matching familiar figures:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Latency</td>
<td>sec</td>
</tr>
<tr>
<td></td>
<td>Errors</td>
<td>errors</td>
</tr>
<tr>
<td></td>
<td>Reaction time</td>
<td>msec</td>
</tr>
<tr>
<td></td>
<td>Mean reaction time</td>
<td>msec</td>
</tr>
<tr>
<td>Clinical</td>
<td>Conners’ rating</td>
<td>0-30 points</td>
</tr>
<tr>
<td></td>
<td>Conners’ teacher</td>
<td>0-50 points</td>
</tr>
<tr>
<td>Psychophysiology</td>
<td>Digital pulse volume (DPV) (individual range corrections):</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$g_{ix} = \frac{DPV_i(x) - DPV_i(min)}{DPV_i(max) - SE_i(min)}$</td>
<td>Mean number of mm over a period of every 10 sec during 10-min relaxation</td>
</tr>
<tr>
<td></td>
<td>Skin conductance (SC)(individual range corrections):</td>
<td>Mean SC level in mho every 10-min relaxation</td>
</tr>
<tr>
<td></td>
<td>$g = \frac{SC_i(x) - SC_i(min)}{SC_i(max) - SC_i(min)}$</td>
<td></td>
</tr>
</tbody>
</table>

However, an interesting observation made by parents of three HK children on ACTH 4-9 was that their children were more sociable while on the peptide. That observation was supported by a reduction in the Conners’ HK index as rated by the teacher. The improvement in sociability was not accompanied by changes in mood of a dysphoric nature as was reported by Rapoport and co-workers\textsuperscript{11} for d-amphetamine and methylphenidate. Additionally, no physical and/or psychological side effects were reported and observed by any HK child while on ACTH 4-9 analog.

The future implications of these findings for studies with ACTH 4-9 analog suggest that single case studies methodology\textsuperscript{12} with a time-series orientation \textsuperscript{13} is warranted.

Acknowledgments

The authors wish to thank Drs. Jean-Paul Bouchard, André Côté, and Faudry Pierre-Louis for clinical support; Ken Laprade, Ginette Pharand-Lefebvre and Louise Blais for technical assistance; and R. Sawdon, N. LeQuéré and G. Savoie-Durette for secretarial assistance. They also thank the Scientific Development Group, Organon International B.V., Oss, The Netherlands, for supplies of ACTH 4-9 analog and for financial support.

References


9. HILL, M.A. (1979) BMDP Statistical Software, Dept. of Biomathematics, UCLA, Los Angeles, California, P2V.


Inquiries and reprint requests should be addressed to:

Dr. H. J. Butter
CH Pierre-Janet
20 Pharand Street
Hull, Québec
Canada
J9A 1K7